This report was first published by Endpoints News. To see the original version, click here
After selling Morphic Therapeutic to Eli Lilly for $3.2 billion, Praveen Tipirneni is back a year and a half later with a new biotech working in Morphic’s old wheelhouse of inflammatory bowel disease.
Caldera Therapeutics emerged from stealth Wednesday with a total of $112.5 million in funding for a bispecific licensed from the Chinese biotech Qyuns Therapeutics.
您已阅读11%（454字），剩余89%（3726字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。